$92 Million

Oyster Point Pharma, Inc.

Initial Public Offering

Bookrunner, October 2019

Oyster Point Pharma, Inc.
Oyster Point, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. The Company’s novel approach leverages the parasympathetic nervous system to stimulate natural tear film production and re-establish tear film homeostasis. The Company’s lead product candidate, OC-01, is a highly selective nAChR agonist being developed as a nasal spray to treat the signs and symptoms of dry eye disease (DED).